Replies to post #217492 on Biotech Values

[semi_infinite]

myok - what happened to Maverick HCM trial planned to study non-obstructive HCM mentioned in last years PR? That would be a much larger potential market than oHCM. I also wonder if N of 200-250 is big enough to address uncertainty wrt AF recurrence or initiation. HCM patients have around 2% incidence of AF per year. People with AF 12 months prior or on certain AADs were excluded in Pioneer.